ZEOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZEOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zeo ScientifiX's Enterprise Value is $-472 Mil. Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-1,017 Mil. Therefore, Zeo ScientifiX's EV-to-EBIT ratio for today is 0.46.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Zeo ScientifiX's Enterprise Value is $-472 Mil. Zeo ScientifiX's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-998 Mil. Therefore, Zeo ScientifiX's EV-to-EBITDA ratio for today is 0.47.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Zeo ScientifiX's Enterprise Value is $-472 Mil. Zeo ScientifiX's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $1,157 Mil. Therefore, Zeo ScientifiX's EV-to-Revenue ratio for today is -0.41.
The historical data trend for Zeo ScientifiX's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 16.14 | 154.02 | 69.79 | 37.52 | 11.83 |
Zeo ScientifiX Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Enterprise Value | Get a 7-Day Free Trial | 23.56 | 14.47 | 24.93 | 11.83 | -474.16 |
For the Biotechnology subindustry, Zeo ScientifiX's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Zeo ScientifiX's Enterprise Value for the fiscal year that ended in Oct. 2023 is calculated as
Enterprise Value (A: Oct. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 12.8917596 | + | 0 | + | 0.013 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.68 | + | 0 | - | 1.756 |
= | 12 |
Zeo ScientifiX's Enterprise Value for the quarter that ended in Jan. 2024 is calculated as
Enterprise Value (Q: Jan. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 7.8406144 | + | 0 | + | 17 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 673 | + | 0 | - | 1172 |
= | -474 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (OTCPK:ZEOX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zeo ScientifiX's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -471.832 | / | -1017.329 | |
= | 0.46 |
Zeo ScientifiX's current Enterprise Value is $-472 Mil.
Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,017 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zeo ScientifiX's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -471.832 | / | -998.154 | |
= | 0.47 |
Zeo ScientifiX's current Enterprise Value is $-472 Mil.
Zeo ScientifiX's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-998 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Zeo ScientifiX's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -471.832 | / | 1157.489 | |
= | -0.41 |
Zeo ScientifiX's current Enterprise Value is $-472 Mil.
Zeo ScientifiX's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,157 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Zeo ScientifiX's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Skycrest Holdings, Llc | 10 percent owner | 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020 |
Harry L. Leider | director, officer: CEO and Director | C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
Howard Lawrence Golub | officer: Executive Vice President & CSO | 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148 |
Matthew Phillip Sinnreich | officer: COO and Acting CEO | 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139 |
Steven Jerry Glauser | director | 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131 |
Leathem S Stearn | director | 2306 BAY DRIVE, POMPANO BEACH FL 33062 |
Charles Luther Bretz | director | 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432 |
Bhupendra Kumar Modi | director | 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985 |
Gurvinder Pal Singh | director | E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048 |
John F Chiste | director | |
Ryan C Likes | officer: Chief Operating Officer | 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019 |
Greyt Ventures, Llc | 10 percent owner | GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
Wendy Grey | 10 percent owner | GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
Ian T Bothwell | 10 percent owner, officer: Chief Financial Officer | 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211 |
Albert Mitrani | director, officer: Chief Executive Officer | 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140 |
From GuruFocus
By PRNewswire PRNewswire • 01-30-2019
By ACCESSWIRE ACCESSWIRE • 08-27-2022
By Marketwired Marketwired • 08-06-2020
By ACCESSWIRE ACCESSWIRE • 02-08-2022
By ACCESSWIRE ACCESSWIRE • 07-20-2022
By ACCESSWIRE ACCESSWIRE • 11-22-2022
By Marketwired Marketwired • 08-13-2020
By Marketwired Marketwired • 05-05-2020
By Marketwired Marketwired • 05-27-2020
By ACCESSWIRE ACCESSWIRE • 06-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.